跳至主要内容
临床试验/CTRI/2020/05/025336
CTRI/2020/05/025336尚未招募3 期

A Phase-III, Open Label, Randomized Controlled Trial Of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment In Asymptomatic Or Mildly Symptomatic Patients With SARS-CoV-2 Infection (Covid-19)

Tata Memorial Centre0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1 Male and Non-pregnant Female
  • 2 Positive reverse-transcriptaseâ??polymerase polymerase chain-reaction (RT-PCR) in a diagnostic specimen
  • 3 Either asymptomatic or have only mild symptoms ((cough and/or fever and/or sore throat and/or other upper respiratory symptoms) at the time of study inclusion
  • 4 Oxygen saturation of >94% while breathing ambient air, if this is measured
  • 5 Either normal levels of haematological, liver and renal functions, and electrolytes OR no worse than Grade 1 (CTCAE Version 5.0) abnormalities in any of these parameters.
  • 6 Patients with high blood sugar or glycosylated haemoglobin, of any degree
  • 7 Arterial blood gas, if done, should have normal values of pH, PO2, PCO2 and bicarbonate levels

排除标准

  • 1 Have pneumonia confirmed by chest imaging, OR
  • 2 Have oxygen saturation (Sao2) of 94% or less while they were breathing ambient air
  • 3 Have any Grade 2 or worse laboratory abnormality, including haematological, renal, liver, electrolyes.

研究者

相似试验